Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 1307

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7A
Chunk 1307
---
31,928,000  
     61,185,000 
  
    Corporate 

     43,409,000 
  
    Research and development 

     8,954,000 
  
    Income from operations 

    $8,822,000 

    Branded  
    ImprimisRx  
    Consolidated 

    Year Ended December 31, 2023 

    Branded  
    ImprimisRx  
    Consolidated 
  
    Product sales, net 
    $37,512,000  
    $79,935,000  
    $117,447,000 
  
    Other revenues 
     12,746,000  
     -  
     12,746,000 
  
    Total revenues 
     50,258,000  
     79,935,000  
     130,193,000 
  
    Cost of sales 
     (12,662,000) 
     (26,978,000) 
     (39,640,000)
  
    Gross profit 
     37,596,000  
     52,957,000  
     90,553,000 
  
    Operating expenses: 

    Selling, general and administrative 
     18,126,000  
     29,210,000  
     47,336,000 
  
    Research and development 
     641,000  
     966,000  
     1,607,000 
  
    Segment contribution 
    $18,829,000  
    $22,781,000  
     41,610,000 
  
    Corporate 

     36,134,000 
  
    Research and development 

     5,045,000 
  
    Income from operations 

    $431,000 

Substantially all revenue is attributable to the
U.S. All long-lived assets at December 31, 2024 and 2023 were located in the U.S.

    F-45

Revenues by segment are further described as follows:

 SCHEDULE
OF REVENUES BY SEGMENT

    For the Years Ended 

    December 31, 

    2024  
    %  
    2023  
    % 
  
    IHEEZO 
    $49,303,000